At the start of enrollment, 56.0 (71.8%) of the patients were on optimal medical HF treatment, including RAAS blockade with ACE inhibitors, AT1 receptor blockers, or ARNIs, in addition to MRAs and beta-blockers. This evidence concerns the gene ACE and hydrops fetalis.